1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Slovakia Pharmaceuticals and Healthcare Report Q2 2016

Slovakia Pharmaceuticals and Healthcare Report Q2 2016

  • March 2016
  • -
  • Business Monitor International
  • -
  • 92 pages

Includes 3 FREE quarterly updates

BMI View: Improving domestic economic outlook will provide a boost to healthcare expenditure inSlovakia in the short term. Over the longer term, we expect healthcare spending to accelerate, givenSlovakia's ageing population and burden of chronic diseases. With public finances on a firmer footing and acentre-left government promising more generous social spending, multinational drugmakers and medicaldevice companies can expect to see growth in revenues from Slovakia.

Headline Expenditure Projections

- Pharmaceuticals: EUR1.91bn (USD2.10bn) in 2015 to EUR1.97bn (USD2.12bn) in 2016; +2.8% inlocal currency terms and +0.6% in US dollar terms. Forecast revised slightly downwards from lastquarter.

- Healthcare: EUR6.27bn (USD6.89bn) in 2015 to EUR6.45bn (USD6.94bn) in 2016; +2.9% in localcurrency terms and +0.7% in US dollar terms. Forecast revised slightly downwards from last quarter.

Table Of Contents

Slovakia Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Slovakia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovakia 2012-2020) 13
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 22
Generic Drug Market Forecast 23
Table: Members Of GENAS, 2015 25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 26
OTC Medicine Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (Slovakia 2014-2020) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Slovakia 2014-2020) 32
Industry Risk/Reward Index 33
Central And Eastern Europe Risk/Reward Index 33
Slovakia Risk/Reward Index 39
Rewards 39
Risks 39
Regulatory Review 41
Regulatory Regime 41
Intellectual Property Issues 44
Pricing Regime 45
Table: Indexed Price Build-Up For Prescription And Non-Prescription Medicines In Slovakia 46
Reimbursement Regime 47
Market Overview 52
Healthcare Sector 53
Table: Healthcare Resources (Slovakia 2010-2015) 55
Table: Healthcare Personnel (Slovakia 2010-2015) 55
Table: Healthcare Activity (Slovakia 2010-2015) 56
Research And Development 60
Table: Members Of BITCET, 2011 61
Table: Members Of SLOVBIOTECH, 2010 62
Clinical Trials 63
Epidemiology 64
Table: Main Causes Of Mortality And Morbidity In Slovakia 65
Competitive Landscape 67
Research-Based Industry 67
Table: Members Of SAFS, 2012 67
Table: Multinational Market Activity 68
Generic Drugmakers 69
Table: Registered Pharmaceutical Manufacturers 69
Pharmaceutical Distribution 70
Table: ADL Members, 2012 (Manufacturers, unless otherwise indicated) 71
Pharmaceutical Retail Sector 71
Company Profile 74
Biotika 74
HBM Pharma 76
Imuna Pharma 79
Demographic Forecast 81
Table: Population Headline Indicators (Slovakia 1990-2025) 82
Table: Key Population Ratios (Slovakia 1990-2025) 82
Table: Urban/Rural Population and Life Expectancy (Slovakia 1990-2025) 83
Table: Population By Age Group (Slovakia 1990-2025) 83
Table: Population By Age Group % (Slovakia 1990-2025) 84
Glossary 86
Methodology 88
Pharmaceutical Expenditure Forecast Model 88
Healthcare Expenditure Forecast Model 88
Notes On Methodology 89
Risk/Reward Index Methodology 90
Index Overview 91
Table: Pharmaceutical Risk/Reward Index Indicators 91
Indicator Weightings 92

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.